GIIDS - GI Inflammatory Diseases Summit

Memo

Delivering higher rates of clinical remission, demonstrating more gut-selective pharmacology and minimizing adverse side effects of your IBD candidate Developed in combination with 20 stakeholders including AbbVie, Theravance and Genentech: GIIDS will be the first end-to-end drug development forum focused exclusively on delivering more clinically safe and efficacious treatments for patients suffering from chronic GI inflammation. Across 3 days of in-depth discussion, share perspectives with industry leaders and overcome translational drug development challenges including: clinical trial design in a hyper-competitive landscape, targeting alternative proinflammatory pathways, and the potential of emerging antigen-specific and bio-therapeutics. Be part of this inaugural summit to collaborate and gain the knowledge you need to confidently navigate the next 12 months of your anti-inflammatory and IBD research. URLs: Brochure: https://go.evvnt.com/392494-0?pid=5569,Tickets: https://go.evvnt.com/392494-2?pid=5569. Prices:Conference + 1 Workshop: USD 3498.0,Conference Only: USD 2899.0,Workshop Only: USD 699.0. Time: 8:00 am to 5:00 pm. Venue details: Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States.